Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials

CTR Vegivinti, KW Evanson, H Lyons, I Akosman… - BMC Infectious …, 2022 - Springer
Abstract Background Coronavirus disease 2019 (COVID-19) continues to pose a significant
threat to public health worldwide. The purpose of this study was to review current evidence …

SARS-CoV-2 one year on: evidence for ongoing viral adaptation

TP Peacock, R Penrice-Randal… - Journal of General …, 2021 - microbiologyresearch.org
SARS-CoV-2 is thought to have originated in the human population from a zoonotic spillover
event. Infection in humans results in a variety of outcomes ranging from asymptomatic cases …

Characterization of the SARS-CoV-2 ExoN (nsp14ExoN–nsp10) complex: implications for its role in viral genome stability and inhibitor identification

HT Baddock, S Brolih, Y Yosaatmadja… - Nucleic acids …, 2022 - academic.oup.com
The SARS-CoV-2 coronavirus is the causal agent of the current global pandemic. SARS-
CoV-2 belongs to an order, Nidovirale s, with very large RNA genomes. It is proposed that …

Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic

D Vlachakis, E Papakonstantinou, T Mitsis… - Food and Chemical …, 2020 - Elsevier
The novel coronavirus SARS-CoV-2 has emerged as a severe threat against public health
and global economies. COVID-19, the disease caused by this virus, is highly contagious and …

Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity

AJW Te Velthuis, TG Zubkova, M Shaw… - Antimicrobial Agents …, 2021 - Am Soc Microbiol
Infections with respiratory viruses constitute a huge burden on our health and economy.
Antivirals against some respiratory viruses are available, but further options are urgently …

[HTML][HTML] Фармакотерапия острых респираторных инфекций, вызванных вирусами гриппа

СК Зырянов, ОИ Бутранова, ДС Гайдай… - Терапевтический …, 2021 - cyberleninka.ru
Вирус гриппа рутинно вносит наиболее весомый вклад в формирование ежегодного
уровня заболеваемости острыми респираторными инфекциями с пиком в зимний …

Innate immunology in COVID-19—a living review. Part I: viral entry, sensing and evasion

C Coveney, M Tellier, F Lu… - Oxford Open …, 2020 - academic.oup.com
The coronavirus infectious disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a world health concern and can …

Enisamium inhibits sars-cov-2 rna synthesis

S Elli, D Bojkova, M Bechtel, T Vial, D Boltz, M Muzzio… - Biomedicines, 2021 - mdpi.com
Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called coronavirus
disease 2019 (COVID-19). While control of the SARS-CoV-2 spread partly depends on …

Pharmacotherapy for acute respiratory infections caused by influenza viruses: current possibilities

S Zyryanov, O Butranova, D Gaidai, K Kryshen - 2021 - covid19.neicon.ru
Routinely the influenza virus significantly contributes to the formation of the annual
incidence of acute respiratory infections, with a peak in winter season. The high level of …

[HTML][HTML] Diamond Light Source: contributions to SARS-CoV-2 biology and therapeutics

MA Walsh, JM Grimes, DI Stuart - Biochemical and Biophysical Research …, 2021 - Elsevier
The impact of COVID-19 on public health and the global economy has led to an
unprecedented research response, with a major emphasis on the development of safe …